Abstract
A pharmacokinetic evaluation of a potential drug interaction between zidovudine (AZT) and dideoxycytidine (ddC) was conducted in monkeys. Each of six animals received 20 mg/kg of AZT intragastrically in the absence and presence of an intravenous steady-state dosage regimen of ddC. The regimen was designed to produce steady-state ddC plasma concentration of 1.77 µg/ml for 30 min. Plasma and urine samples were analyzed for AZT, its major glucuronide metabolite, GAZT, and ddC by HPLC techniques. Pharmacokinetic parameters for AZT and GAZT were calculated by non-compartmental methods. The mean apparent clearance of AZT was 1.40 and 1.78 L/hr/kg in the absence and presence of ddC, respectively. The mean AUC for GAZT was 36.39 µg-hr/ml in the absence of ddC and 28.81 µg-hr/ml in the presence of ddC. No statistical differences were found in these and other pharmacokinetic parameters in the absence and presence of ddC. The absence of an effect on AZT's pharmacokinetics by ddC is attributed to the primary metabolic and renal elimination pathways for AZT and ddC, respectively. The results of this study provide a rational basis to design combined AZT-ddC treatment regimens in AIDS patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
H. Mitsuya and S. Broder. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleoside. Proc. Natl. Acad. Sci. USA 83:1911–1915 (1986).
D. D. Richman. Results of continued monitoring of participants in the placebo-controlled trial of Zidovudine for serious human immunodeficiency virus infection. Am. J. Med. 88 (Suppl 2A):208–212 (1988).
T. C. Merigan, G. Skowron, S. A. Bozzette, D. Richman, R. Uttamchandani, M. Fischl, R. Schooley, M. Hirsch, W. Soo, C. Pellinelli, H. Schaumburg, and the ddC Study Group of AZID Clinical Trials. Circulating 24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV/Infection). Ann. Intern. Med. 110:189–194 (1989).
B. A. Larder, G. Darby, and D. D. Richman. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731–1734 (1989).
T. C. Meng, M. A. Fischl, and D. D. Richman. AIDS clinical trials group: Phase I/II study of combination 2′,3′,dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex. Am. J. Med. 88 (Suppl 5B):275–305 (1990).
M. Baba, R. Pounds, J. Balzarini, P. Herdewijn, E. D. Clercq, and J. Desmyter. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 31:1613–1617 (1987).
H. D. Langtry and D. M. Campolin-Richards. Zidovudine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 37:408–450 (1989).
S. S. Good, D. T. Durack, and P. de Miranda. Biotransformation in various species and in humans of 3′-azido-3′-deoxythymidine, a potential agent for the treatment of AIDS. Fed. Proc. 45:444 (1986).
J. A. Kelley, C. L. Letterst, J. S. Roth, D. T. Vistica, D. G. Poplack, D. A. Cooney, M. Nadkarni, F. M. Balis, S. Broder, and D. G. Johns. The disposition and metabolism of 2′,3′-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab. Dispos. 15:595–601 (1987).
P. de Miranda, T. C. Burnette, and S. S. Good. Tissue distribution and metabolic disposition of zidovudine in rats. Drug Metab. Dispos. 18:315–320 (1990).
S. S. Good, C. S. Koble, R. Crouch, R. L. Johnson, J. L. Rideout, and P. de Miranda. Isolation and characterization of an ether glucuronide of zidovudine, a major metabolite in monkeys and humans. Drug Metab. Dispos. 18:321–326 (1990).
M. Qian, T. S. Finco, and J. M. Gallo. Rapid and simultaneous determination of zidovudine and its glucuronide metabolite in plasma and urine. J. Pharm. Biomed. Anal. 9:275–279 (1991).
M. L. Rocci and W. J. Jusko. LAGRAN program for area and moments in pharmacokinetic analysis. Comp. Prog. Biomed. 16:203–216 (1983).
D. M. Kornhauser, B. G. Petty, C. W. Hendrix, A. S. Woods, L. J. Nerhood, J. G. Bratlett, and P. S. Lietman. Probenecid and zidovudine metabolism. Lancet 2(8661):473–475 (1989).
P. de Miranda, S. S. Good, R. Yarchoan, R. V. Thomas, M. R. Blum, C. E. Myers, and S. Broder. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin. Pharmacol. Ther. 46:494–500 (1989).
M. Qian, T. S. Finco, M. Mehta, C. T. Vishwanathan, and J. M. Gallo. Pharmacokinetic evaluation of drug interaction with zidovudine, I. Probenecid and zidovudine in monkeys. J. Pharm. Sci. 80:1007–1011 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Qian, M., Swagler, A.R., Mehta, M. et al. Pharmacokinetic Evaluation of Drug Interactions with Anti-Human Immunotrophic Virus (HIV) Drugs. III. 2′,3′-Dideoxycytidine (ddC) and Zidovudine in Monkeys. Pharm Res 9, 224–227 (1992). https://doi.org/10.1023/A:1018941507979
Issue Date:
DOI: https://doi.org/10.1023/A:1018941507979